RT from @KDAO2011"When Ustekinumab was developed, it was accidental that the p40 subunit targeted blocked both IL-12 and IL-23 (original intent to block only IL23) blocking I12 may decrease response to IL-23. this drug is better for skin than for joints - Dr. E Ruderman #RNL2021